Atara生物治療 ATRA 深 滬
已收盤 02-06 16:00:00 美东时间
4.88
+0.370
+8.20%
華盛通- 最 高4.92
- 今 開4.58
- 成交量 10.00万股
- 最 低 4.58
- 昨 收 4.51
- 總市值 3518.59万
- 52周最高 19.145
- 市盈率 靜 --
- 換手率 1.39%
- 52周最低 4.20
- 委 比 -28.21%
- 總股本 721.02万
- 歷史最高 1639.00
- 量 比 0.81
- 振 幅 7.54%
- 歷史最低 4.20
- 每 手 1
- 風險率 3.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atara's Outlook As Ebvallo Hits Second FDA CRL
Manufacturing Fixed, But Trial Interpretability Now Blocks US Approval Drug &am...
01-15 02:28
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6
Canaccord Genuity analyst John Newman downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $25 to $6.
01-14 04:17
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
An update from Atara Biotherapeutics ( ($ATRA) ) is now available. On January 1...
01-13 05:40
FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks
Atara Biotherapeutics stock drops on FDA rejection of EBVALLO BLA for serious post-transplant complication. FDA raises new concerns.
01-13 00:06
Atara Biotherapeutics shares are trading lower. The company announced that it has agreed to reduce the milestone payments from Pierre Fabre from $40 million to $31 million, while securing rights to an additional $15 million commercial milestone payment.
Atara Biotherapeutics shares are trading lower. The company announced that it h...
01-07 01:03
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25
Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and raises the price target from $17 to $25.
2025-12-19 23:07
Atara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.86) by 62.79 percent. This is a 89.08 percent increase over losses of $(2.93) per share
2025-11-12 22:06
Pierre Fabre Pharmaceuticals Takes Over Tabelecleucel BLA From Atara Biotherapeutics Ahead Of FDA Priority Review On January 10, 2026 For First U.S. EBV+ PTLD Therapy
Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDUFA) target action
2025-11-03 22:18
